Journal
MOLECULAR THERAPY
Volume 26, Issue 5, Pages 1215-1227Publisher
CELL PRESS
DOI: 10.1016/j.ymthe.2018.02.025
Keywords
-
Categories
Funding
- National Institute of Health Research (NIHR) [RP-2014-05-007]
- NIHR Blood and Transplant Research Unit (BTRU) [BTRU-2014-10074]
- Great Ormond Street Biomedical Research Centre [IS-BRC-1215-20012]
- Children with Cancer [2014/171]
Ask authors/readers for more resources
Gene editing can be used to overcome allo-recognition, which otherwise limits allogeneic T cell therapies. Initial proof-of-concept applications have included generation of such universal T cells expressing chimeric antigen receptors (CARs) against CD19 target antigens combined with transient expression of DNA-targeting nucleases to disrupt the T cell receptor alpha constant chain (TRAC). Although relatively efficient, transgene expression and editing effects were unlinked, yields variable, and resulting T cell populations heterogeneous, complicating dosing strategies. We describe a self-inactivating lentiviral terminal vector platform coupling CAR expression with CRISPR/Cas9 effects through incorporation of an sgRNA element into the Delta U3 3' long terminal repeat (LTR). Following reverse transcription and duplication of the hybrid Delta U3-sgRNA, delivery of Cas9 mRNA resulted in targeted TRAC locus cleavage and allowed the enrichment of highly homogeneous (> 96%) CAR(+) (> 99%) TCR- populations by automated magnetic separation. Molecular analyses, including NGS, WGS, and Digenome-seq, verified on-target specificity with no evidence of predicted off-target events. Robust anti-leukemic effects were demonstrated in humanized immunodeficient mice and were sustained longer than by conventional CAR(+)TCR(+) T cells. Terminal-TRAC (TT) CAR T cells offer the possibility of a pre-manufactured, non-HLA-matched CAR cell therapy and will be evaluated in phase 1 trials against B cell malignancies shortly.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available